Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 17.19 is 60% above its 3-year average of 10.74, around the middle of its 3-year range (0.00–24.76).
As of the fiscal period ended Tuesday, June 30, 2026. 5.74% above its 12-month average of 16.25.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 17.19.
QUICK RATIO (ACID-TEST)
17.19
QUICK RATIO (ACID-TEST) AVG TTM
16.25
QUICK RATIO (ACID-TEST) AVG 3Y
13.90
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+5.74%
CURRENT VS 3Y AVG
+23.65%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 568 covered companies
CURRENT VS SECTOR MEDIAN
+474.87%
vs the sector median at left
BioAge Labs Inc.
Market Cap
$234.93M
Quick Ratio (Acid-Test)
17.19
TTM Avg
16.25
3Y Avg
13.90
5Y Avg
N/A
Market Cap
$236.90M
Quick Ratio (Acid-Test)
1.35
TTM Avg
1.13
3Y Avg
1.14
5Y Avg
1.18
Market Cap
$231.69M
Quick Ratio (Acid-Test)
2.96
TTM Avg
4.42
3Y Avg
4.46
5Y Avg
4.62
Market Cap
$239.06M
Quick Ratio (Acid-Test)
0.10
TTM Avg
1.46
3Y Avg
1.56
5Y Avg
2.73
Market Cap
$240.50M
Quick Ratio (Acid-Test)
2.85
TTM Avg
2.31
3Y Avg
2.01
5Y Avg
2.00
Market Cap
$240.76M
Quick Ratio (Acid-Test)
0.81
TTM Avg
0.81
3Y Avg
0.76
5Y Avg
0.71
Market Cap
$243.66M
Quick Ratio (Acid-Test)
1.54
TTM Avg
1.17
3Y Avg
19.33
5Y Avg
29.22
Market Cap
$243.81M
Quick Ratio (Acid-Test)
2.69
TTM Avg
2.01
3Y Avg
1.61
5Y Avg
1.29
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioAge Labs Inc. (BIOA) | $234.93M | 17.19 | 16.25 | 13.90 | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.90M | 1.35 | 1.13 | 1.14 | 1.18 |
| MacroGenics, Inc. (MGNX)vs › | $231.69M | 2.96 | 4.42 | 4.46 | 4.62 |
| Galectin Therapeutics Inc. (GALT)vs › | $239.06M | 0.10 | 1.46 | 1.56 | 2.73 |
| Biodesix, Inc. (BDSX)vs › | $240.50M | 2.85 | 2.31 | 2.01 | 2.00 |
| High Tide Inc. (HITI)vs › | $240.76M | 0.81 | 0.81 | 0.76 | 0.71 |
| InflaRx N.V. (IFRX)vs › | $241.56M | 8.22 | 4.35 | 5.50 | 5.94 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.66M | 1.54 | 1.17 | 19.33 | 29.22 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | 2.69 | 2.01 | 1.61 | 1.29 |
| Keros Therapeutics, Inc. (KROS)vs › | $225.44M | 21.96 | 18.45 | 17.11 | 21.15 |
Quick Ratio
17.19
Excludes inventory
Current Ratio
17.19
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 17.19 |
| 2026-03-31 | 24.76 |
| 2025-12-31 | 14.24 |
| 2025-09-30 | 11.87 |
| 2025-06-30 | 13.21 |
| 2025-03-31 | 13.68 |
| 2024-12-31 | 12.86 |
| 2024-09-30 | 17.63 |
| 2024-06-30 | 12.61 |
| 2024-03-31 | 11.81 |
| 2023-12-31 | 0.44 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
